Skip to content

Evaluation of Whole Body Examination by MRI Integrating the Zero Time Eco Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner

Evaluation of Whole Body Examination by MRI Integrating the Zero Time Eco Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body Scanner

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05381077
Acronym
MM-ZTE
Enrollment
30
Registered
2022-05-19
Start date
2021-02-02
Completion date
2023-08-31
Last updated
2022-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases, Multiple Myeloma

Keywords

MRI, Zero time echo

Brief summary

To assess the added value of magnetic resonance imaging (MRI) of the skeleton compared to other validated techniques for the detection of bone lesions in patients with multiple myeloma.

Detailed description

The aim of our study is to offer patients benefiting from a diagnostic approach to myeloma by PET / CT, a whole body MRI examination (MRI-CE) comprising, in addition to the classic bone marrow sequences, a ZTE sequence (see below) . This study is being undertaken to compare and assess the complementarity of imaging techniques in the diagnostic management of this disease. The stages of the work will be: Optimizing bone marrow exploration sequences by MRI (F. Lecouvet, N. Michoux, Gaetan Duchêne). Develop and validate a whole body-wide new MRI sequence ZTE capable of detecting and quantifying disease-induced osteolysis in the skeleton. Optimize the reconstruction of these images (Deep Learning software developed with the firm GE), training of the reconstruction of ZTE images by correlation with the scanner (F. Lecouvet, N. Michoux, Gaetan Duchêne). This approach is completely original, never having been evaluated: the ZTE sequence is a recent development, made available at CUSL on the new research MRI magnet. The addition of this sequence to the already major information provided by MRI for the detection of the disease and the evaluation of its response (method of choice, see below) would constitute a major advance in establishing the diagnostic value of this technique. non-irradiating compared to other techniques (PET-CT, low dose scanner, etc.).

Interventions

OTHERMRI

Whole body MRI (ZTE sequence)

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Whole body MRI in addition to the classic PET / CT assessment for all participant.

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patient with newly diagnosed multiple myeloma, for whom bone imaging is required for staging. * Recurrent patient after intensive treatment (high dose chemotherapy, bone marrow transplant, etc.). * Patient requiring a PET / CT considered as the technique of choice in these stages of the disease.

Exclusion criteria

* Implanted material incompatible with MRI. * Severe claustrophobia. * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the diagnostic performance of the different imaging protocolsthrough study completion, an average of 1 yearThe diagnostic performance of the different imaging protocols will be evaluated by analyzing the receptor efficiency function (ROC curve) and by estimating the Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV), Negative Predictive Value (NPV) ) as well as the Predictive Accuracy (Acc) of the different imaging protocols.
Comparison of Sensitivity (Se) and Predictive Precision (Acc) of the different imaging protocolsthrough study completion, an average of 1 yearMcNemar test on paired data. The Gold Standard will be determined by a panel of independent experts based on all available imaging techniques.

Countries

Belgium

Contacts

Primary ContactFrederic Lecouvet, MD-PhD
frederic.lecouvet@uclouvain.be+3227642793
Backup Contactperrine Triqueneaux
perrine.triqueneaux@uclouvain.be+3227642935

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026